Leerink Partnrs Increases Earnings Estimates for Compugen

Compugen Ltd. (NASDAQ:CGEN) – Leerink Partnrs upped their FY2025 earnings per share (EPS) estimates for shares of Compugen in a research report issued on Monday, November 10th. Leerink Partnrs analyst D. Graybosch now anticipates that the biotechnology company will post earnings per share of ($0.31) for the year, up from their previous forecast of ($0.38). The consensus estimate for Compugen’s current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Compugen’s Q4 2025 earnings at ($0.08) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.08) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.33) EPS, FY2027 earnings at ($0.31) EPS, FY2028 earnings at ($0.33) EPS and FY2029 earnings at $0.18 EPS.

Compugen (NASDAQ:CGEN) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.09) by $0.02. The company had revenue of $1.89 million for the quarter, compared to analyst estimates of $1.47 million. Compugen had a negative return on equity of 34.77% and a negative net margin of 87.45%.

A number of other analysts have also recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Compugen in a research report on Wednesday, October 8th. Wall Street Zen cut shares of Compugen from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $4.00.

Compugen Stock Up 0.6%

Shares of CGEN stock traded up $0.01 during trading hours on Thursday, reaching $1.69. 26,752 shares of the stock traded hands, compared to its average volume of 394,074. The business has a fifty day moving average price of $1.63 and a 200 day moving average price of $1.56. Compugen has a 1-year low of $1.13 and a 1-year high of $2.66. The firm has a market capitalization of $150.81 million, a PE ratio of -7.66 and a beta of 2.59.

Institutional Investors Weigh In On Compugen

Several large investors have recently made changes to their positions in CGEN. ARK Investment Management LLC acquired a new stake in Compugen in the 1st quarter valued at $1,323,000. US Bancorp DE purchased a new stake in Compugen in the first quarter worth approximately $29,000. Schnieders Capital Management LLC bought a new position in shares of Compugen during the first quarter valued at about $131,000. R Squared Ltd purchased a new position in shares of Compugen in the 2nd quarter valued at approximately $71,000. Finally, Franklin Resources Inc. purchased a new position in Compugen in the second quarter worth about $56,000. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.